PFKFB2

Across TCGA pan-cancer cohorts, PFKFB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PFKFB2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PFKFB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PFKFB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where PFKFB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.678	0.263	.001	56	view →
LUAD	OS	Median	All	0.888	0.658	.004	27	view →
UCEC	OS	Tertile	All	1.000	0.851	.006	12	view →
CCRCC	DFS	Quartile	All	0.912	0.440	<.001	8	view →
LSCC	DFS	Quartile	III,IV	0.472	0.941	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PFKFB2–PDAC (DFS)

Open the PDAC breakdown →